At a glance
ClinicalIndex Comparison RecordPhase 3Not Yet Recruiting· 5,276 target
Drug / intervention
Recaticimab +1 moredrug
Likely dose
Recaticimab 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis (PICASSO): A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University·interventional·Posted Aug 13, 2025·Updated Aug 13, 2025
In Brief
A Phase 3 clinical trial evaluating Recaticimab and Placebo for Symptomatic Intracranial Atherosclerotic Stenosis. Not yet recruiting, targeting 5,276 participants across 1 site.
Detailed Summary
An investigator-initiated, prospective, multicenter, randomized, double-blind, placebo-controlled trial comparing the 1-year incidence of stroke in patients with AIS or TIA within 7 days who are treated with either placebo or Recaticimab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 3Not Yet Recruiting
20262027202820292030
First PostedAug 2025
Enrollment StartSep 2025
TodayJul 2026
Primary CompletionDec 2029
First PostedAug 13, 2025
Enrollment StartSep 1, 2025
Primary CompletionDec 1, 2029
TodayJul 1, 2026
Enrollment to primary: 4.3 yearsPosted 11 months agoPrimary completion in 3.4 years
Interventions
Recaticimabdrug
Recaticimab 300mg subcutaneous Q8W for 1 year.
Placebodrug
Matched placebo subcutaneous Q8W for 1 year.